Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Northside Hospital, Inc.
- Registration Number
- NCT06337331
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Avapritinib With Decitabine in Patients With SM-AHN
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 34
- Registration Number
- NCT06327685
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT06297772
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 27
- Registration Number
- NCT06156579
- Locations
- 🇩🇪
University Hospital, Tuebingen, Baden-Wuerttemberg, Germany
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Benjamin Tomlinson
- Target Recruit Count
- 20
- Registration Number
- NCT06129734
- Locations
- 🇺🇸
University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 40
- Registration Number
- NCT05983276
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Decitabine for Poor Graft Function Post Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Target Recruit Count
- 76
- Registration Number
- NCT05907499
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- PureTech
- Target Recruit Count
- 90
- Registration Number
- NCT05829226
- Locations
- 🇺🇸
Mass. General Hospital-Harvard, Boston, Massachusetts, United States
🇺🇸Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
🇺🇸Baptist Health South Florida-Miami Cancer Institute, Miami, Florida, United States
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05816356
- Locations
- 🇺🇸
Worldwide Clinical Trails Early Phase Services, San Antonio, Texas, United States
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT05805072
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.